$6.21
+1.5%Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.
SRTA • NASDAQ
| Strata Critical Medical, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
41.3M | -27.3M | -56.1M | -27.3M | -40.1M | -10.2M | -10.8M | |
8.2M | 6M | 7.1M | 5.7M | 596K | 526K | 472K | |
432K | -255K | -1.5M | -772K | -3.6M | 0.0 | 0.0 | |
17.8M | 19.9M | 12.5M | 8.3M | 9.6M | 490K | 317K | |
-107.6M | 2.2M | 12.3M | -23.1M | 20.1M | 0.0 | 28K | |
(87K) | (0.0) | (16K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-9.1M | -3M | -6.7M | -17K | -2.2M | -1.7M | -281K | |
-48.9M | -2.5M | -32.3M | -37.1M | -15.6M | -10.8M | -10.3M | |
INVESTING ACTIVITIES | |||||||
-9.6M | -30.9M | -2.1M | -730K | -297K | -377K | -604K | |
-66.5M | -2.2M | -39K | -48.1M | -23.1M | (0.0) | -200K | |
-146.3M | -143.3M | -266M | -228.2M | -308.8M | (0.0) | (0.0) | |
75.4M | 177.5M | 285.1M | 356.4M | 11.3M | 0.0 | 0.0 | |
216.8M | -2.1M | 138K | 0.0 | -504K | 0.0 | -250K | |
(69.8M) | -1M | (17.1M) | (79.3M) | -321.3M | -377K | -1.1M | |
FINANCING ACTIVITIES | |||||||
193K | -244K | 0.0 | 87K | 119.6M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -1.2M | 1.2M | 0.0 | |
(0.0) | -244K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-9.1M | -5.5M | -76K | -1.2M | 213.8M | 15K | 116K | |
-8.9M | -5.8M | -76K | -1.1M | 332.3M | 1.2M | 116K | |
CASH FLOW SUMMARY | |||||||
3M | -80K | -66K | -4.3M | 0.0 | 0.0 | 0.0 | |
14.9M | -9.4M | -15.4M | 36.8M | -4.7M | -10M | -11.2M | |
19.6M | 29M | 44.4M | 7.6M | 12.3M | 22.3M | 33.5M | |
31.2M | 19.6M | 29M | 44.4M | 7.6M | 12.3M | 22.3M | |
-58.5M | -35.5M | -34.5M | -37.9M | -16.4M | -11.2M | -11.2M |
SRTA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | May 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 14, 2026 | May 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 02, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | December 02, 2025 | September 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 |
Continue your SRTA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.